Abstract

ObjectiveThis article aims to evaluate the survival benefits of simple cholecystectomy, extended cholecystectomy, as well as scope regional lymphadenectomy for T2 gallbladder cancer (GBC) patients.MethodsWe identified eligible patients from the Surveillance, Epidemiology, and End Results database. The confounding factors were controlled via propensity score matching. The log-rank test was utilized to compare overall survival. The multivariate Cox regression was then used to determine risk factors.ResultsOverall, data from 1,009 patients were obtained. The median overall survival (OS) of 915 patients that underwent simple cholecystectomy was 15 months; the median OS of 94 patients that underwent extended cholecystectomy was 17 months. There were no significant differences before and after propensity score matching (p = 0.542 and p = 0.258). The patients who received regional lymphadenectomy did show significant survival benefit, compared to those who did not receive regional lymphadenectomy. Furthermore, this benefit is observed in the N0 stage, but not observed in the N1 stage. In addition, the OS of patients who received lymphadenectomy for four or more regions was significantly better than those who received one to three regions lymphadenectomy. Age, the scope of regional lymphadenectomy, N stage, and tumor size were identified as prognostic factors.ConclusionsExtended cholecystectomy was not observed to significantly improve postoperative prognosis of patients with T2 GBC. However, there was a significant survival benefit shown for those with regional lymphadenectomy, particularly for patients with negative lymph nodes. Future studies on the control of potential confounding factors and longer follow-ups are still needed.

Highlights

  • Gallbladder cancer (GBC) is one of the most common malignant tumors of the biliary system and accounts for about 46%

  • Compared to the 7th edition of “American Joint Committee on Cancer (AJCC) Tumor TNM Staging Manual”, the 8th edition subdivides the T2 stage into T2a stage and T2b stage

  • The database has continuously collected data on cancer incidence, prevalence, and survival of patients from 18 regional registries and tracks approximately 34.6% of the United States population. In this population-based retrospective cohort study, we evaluated prognosis of patients that were diagnosed with primary T2 GBC whose clinical data were incorporated to the SEER database between 2010 and 2015

Read more

Summary

Methods

We identified eligible patients from the Surveillance, Epidemiology, and End Results database. The confounding factors were controlled via propensity score matching. The log-rank test was utilized to compare overall survival. The multivariate Cox regression was used to determine risk factors

Results
Conclusions
INTRODUCTION
RESULTS
DISCUSSION
CONCLUSION
LIMITATION
DATA AVAILABILITY STATEMENT
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call